Aclaris Therapeutics, Inc. ACRS
Set alert
As of Nov 2, 2:25 PM ET
- YTD
- +25.75%
- 1 year
- +50.20%
- Open
- 3.96
- Prev close
- 3.97
- Mkt cap
- 586.62M
- Vol
- 794.53K
- Avg vol
- 2.91M
- EPS
- -0.58
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.78
- High
- 4.04
- Forward P/E
- -5.00
- Beta
- 0.12
- Short ratio
- 0.47
- Inst. own
- 90.21%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.70
- 200-d avg
- 1.58
- 1y target
- 10.00
5D chart
Signals (76)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 30, 11:55 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 11:55 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:25 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:45 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 1:50 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 1:15 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 4 days ago |
| RSI: Overbought | Oct 29, 10:15 AM | 4 days ago |
| RSI: Overbought | Oct 28, 3:50 PM | 4 days ago |
| RSI: Overbought | Oct 28, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:35 PM | 5 days ago |
| RSI: Oversold | Oct 28, 12:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:15 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:15 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 2:55 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:45 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 1:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 1:25 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 1:20 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:05 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 1:05 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 1:00 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 6 days ago |
| SMA: Bullish | Oct 27, 11:15 AM | 6 days ago |
| SMA: Bullish | Oct 27, 11:15 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 6 days ago |
| MACD: Buy Signal | Oct 27, 10:30 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 6 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 6 days ago |
| RSI: Oversold | Oct 27, 9:30 AM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 1 week ago |
| SMA: Bearish | Oct 26, 2:20 PM | 1 week ago |
| MACD: Sell Signal | Oct 26, 2:10 PM | 1 week ago |
| MACD: Buy Signal | Oct 26, 2:05 PM | 1 week ago |
| MACD: Sell Signal | Oct 26, 12:50 PM | 1 week ago |
| SMA: Bearish | Oct 26, 11:50 AM | 1 week ago |
| SMA: Bearish | Oct 26, 10:20 AM | 1 week ago |
News
-
2 days ago benzinga.com
Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Raises Price Target to $13
Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and raises the price target from $10 to $13.
-
5 days ago benzinga.com
Wedbush Maintains Outperform on Aclaris Therapeutics, Lowers Price Target to $8
Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and lowers the price target from $10 to $8.
-
5 days ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.
5 days ago marketbeat.com
Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b
Aclaris Therapeutics NASDAQ: ACRS reported Phase 1b proof-of-concept results for ATI-052, its bispecific antibody designed to inhibit thymic stromal lymphopoietin (TSLP) and IL-4 receptor alpha, in…
6 days ago benzinga.com
Aclaris Says Early Data Validates Dual-Target Approach for Eczema, Asthma Drug
Aclaris Therapeutics announces positive Phase 1b trial data for ATI-052 in eczema and asthma alongside a $50 million public financing round.
6 days ago seekingalpha.com
Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript
Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript
6 days ago benzinga.com
Whirlpool Posts Downbeat Q3 Results, Joins HSBC, Hilton Hotels And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. futures rose, but Whirlpool plunged after a major earnings miss and lowered guidance; HSBC, Armstrong World and others also fell premarket.
-
6 days ago benzinga.com
Aclaris Therapeutics Prices $50M Offering Of 7,785,714 Shares And Warrants To Purchase 6.5M Shares At $3.50/Unit
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the pricing of an…
6 days ago globenewswire.com
Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
WAYNE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for…
6 days ago globenewswire.com
Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma
Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis
1 week ago defenseworld.net
Aclaris Therapeutics, Inc. (ACRS) – What Are Analysts Saying About This Stock?
Shares of Aclaris Therapeutics, Inc. (NASDAQ: ACRS - Get Free Report) have earned an average recommendation of "Buy" from the nine brokerages that are covering the firm, Marketbeat Ratings reports.…
1 week ago zacks.com
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here is how Aclaris Therapeutics (ACRS) and Glaukos (GKOS) have performed compared to their sector so far this year.
-
2 weeks ago benzinga.com
Truist Financial, Regions Financial And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures mixed; Truist slips after mixed results, while Telkom Indonesia, Loma Negra, Omeros and others fall premarket.
2 weeks ago benzinga.com
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Alcoa shares rose after Q3 earnings beat estimates; Rubico and others surged, while Nuburu, Jaguar Health and other stocks fell premarket.
3 weeks ago benzinga.com
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.
1 month ago zacks.com
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in…
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose…
2 months ago globenewswire.com
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for…
-
2 months ago benzinga.com
Canaccord Genuity Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $10
Canaccord Genuity analyst Edward Nash initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $10.
2 months ago benzinga.com
Vipshop, Gorilla Technology Group And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures rise, Nasdaq 100 gains 200 points. Vipshop shares fall 4.9% after reporting Q2 earnings below expectations. Other stocks dip in pre-market trading.
2 months ago benzinga.com
Why Cadeler Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Shares of Cadeler A/S (NYSE: CDLR) surged in pre-market trading after reporting strong financial results for the first half of 2026. Revenue and profit increased significantly, and full-year guidance…
2 months ago defenseworld.net
Deutsche Bank AG Makes New Investment in Aclaris Therapeutics, Inc. $ACRS
Deutsche Bank AG purchased a new stake in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) in the second quarter, according to the company in its most recent filing with the Securities and Exchange…
2 months ago zacks.com
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade
The consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate…
2 months ago globenewswire.com
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for…
2 months ago zacks.com
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.13 per share a year ago.
-
2 months ago benzinga.com
Aclaris Therapeutics Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $1.629M Beat $1.383M Estimate
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 6.25 percent. This is a 15.38 percent decrease over losses of…
2 months ago globenewswire.com
Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Timelines Reaffirmed for Upcoming Top Line…
4 months ago zacks.com
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
Aclaris (ACRS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the…
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-market session. The company's market cap stands at $4.4 million. Vivos Therapeutics (NASDAQ:VVOS) shares…
4 months ago marketbeat.com
3 Penny Stocks Under $5 Backed by Real Revenue Growth
Investing in penny stocks requires significant conviction. Many of the companies in this group are purely “story stocks.
4 months ago benzinga.com
SL Science Holding, Alamos Gold And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures mixed. SL Science shares fall 11.4% after reporting financial results. Other stocks also down in pre-market trading.
4 months ago marketbeat.com
3 Penny Stocks Under $5 Backed by Real Revenue Growth
Investing in penny stocks requires significant conviction. Many of the companies in this group are purely “story stocks.
5 months ago marketbeat.com
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052
Aclaris Therapeutics NASDAQ: ACRS executives outlined a busy clinical calendar for the biotechnology company during a fireside chat at the Jefferies 2026 Global Healthcare Conference, highlighting…
5 months ago benzinga.com
This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday
Top Wall Street analysts begin coverage of Aclaris Therapeutics, Orion Group Holdings, and Take-Two Interactive.
5 months ago globenewswire.com
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
WAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for…
5 months ago seekingalpha.com
Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
5 months ago globenewswire.com
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for…
-
5 months ago benzinga.com
Aclaris Therapeutics Q1 EPS $(0.15), Inline, Sales $1.996M Beat $1.322M Estimate
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 25 percent decrease over losses of $(0.12) per share from the…
-
6 months ago benzinga.com
Piper Sandler Maintains Overweight on Aclaris Therapeutics, Raises Price Target to $11
Piper Sandler analyst Biren Amin maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight and raises the price target from $7 to $11.
6 months ago benzinga.com
This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Citations for AMAT, BMEA, ACRS, KALU, SION.
-
6 months ago benzinga.com
Guggenheim Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $12
Guggenheim analyst Seamus Fernandez initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $12.
-
6 months ago benzinga.com
Wedbush Maintains Outperform on Aclaris Therapeutics, Raises Price Target to $10
Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and raises the price target from $8 to $10.
-
6 months ago benzinga.com
Aclaris Therapeutics Announces Top Line Results From Its Phase 1a Single And Multiple Ascending Dose Trial Of Its Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 And The Selection Of Lichen Llanus As The lead Indication For Its Selective ITK/JAK3 Inhibitor ATI-2138
"These results validate that ATI-052 is a highly potent and well tolerated bispecific antibody that has the potential to be highly effective in a variety of inflammatory and immunological disorders,"…
-
6 months ago benzinga.com
Aclaris Therapeutics to Reveal Clinical Update On Key Biologic And Oral Inhibitor Programs on April 28, 2026
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will…
-
6 months ago benzinga.com
Oppenheimer Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Target of $10
Oppenheimer analyst Jeff Jones initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform rating and announces Price Target of $10.
-
7 months ago benzinga.com
Wedbush Reiterates Outperform on Aclaris Therapeutics, Maintains $8 Price Target
Wedbush analyst Martin Fan reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and maintains $8 price target.
-
7 months ago benzinga.com
Aclaris Therapeutics Presents Additional Results From Phase 2a Trial Of ATI-2138, Potent And Selective Investigational Oral Covalent Inhibitor Of ITK And JAK3, At 2026 AAD Annual Meeting
- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life -WAYNE, Pa., March 27, 2026 (GLOBE…
-
7 months ago benzinga.com
Aclaris Therapeutics To Present Results From Open-Label Phase 2a Trial Of ATI-2138, Investigational Oral Covalent Inhibitor Of Interleukin-2-ITK And JAK3, At 2026 AAD Annual Meeting
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an ePoster…
-
7 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.
-
8 months ago benzinga.com
Aclaris Therapeutics Q4 EPS $(0.16) Misses $(0.14) Estimate, Sales $1.295M Miss $1.938M Estimate
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 11.11 percent. This is a 60 percent decrease over losses of…